[Nosocomial infection due to ESBL-producing bacteria].
Yagi
Tetsuya
T
Department of Bacterial Pathogenesis and Infection Control, National Institute of Infectious Diseases.
D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D003428:Cross Infection / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control; D024881:Drug Resistance, Bacterial; D004363:Drug Utilization / Q000706:statistics & numerical data; D004926:Escherichia coli / Q000187:drug effects / Q000201:enzymology / Q000302:isolation & purification; D004927:Escherichia coli Infections / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control; D006801:Humans; D017053:Infection Control; D007710:Klebsiella Infections / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology / Q000517:prevention & control; D007711:Klebsiella pneumoniae / Q000187:drug effects / Q000201:enzymology / Q000302:isolation & purification; D011379:Prognosis; D012307:Risk Factors; D001618:beta-Lactamases / Q000096:biosynthesis*
D000900:Anti-Bacterial Agents; D001618:beta-Lactamases